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Sep. 29, 1998 5,814,473 FIG This invention relates to newly identified polynucleotides, polypeptides encoded by Such polynucleotides, the use of Such polynucleotides and polypeptides, as well as the production and isolation of Such polynucleotides and polypeptides. More particularly, the polynucleotides and polypeptides of the present invention have been putatively identified as transaminases and/or aminotransferases. Aminotransferases are enzymes that catalyze the transfer of amino groups from C-amino to C.-keto acids. They are also called transaminases.
The C-amino groups of the 20 L-amino acids commonly found in proteins are removed during the oxidative degra dation of the amino acids. The removal of the C-amino groups, the first Step in the catabolism of most of the L-amino acids, is promoted by aminotransferases (or transaminases). In these transamination reactions, the C.-amino group is transferred to the C-carbon atom of C.-ketoglutarate, leaving behind the corresponding O-keto acid analog of the amino acid. There is no net deamination (i.e., loss of amino groups) in Such reactions because the C.-ketoglutarate becomes aminated as the C-amino acid is deaminated. The effect of transamination reactions is to collect the amino groups from many different amino acids in the form of only one, namely, L-glutamate. The glutamate channels amino groups either into biosynthetic pathways or into a final Sequence of reactions by which nitrogenous waste products are formed and then excreted.
Cells contain Several different aminotransferases, many Specific for C-ketoglutarate as the amino group acceptor. The aminotransferases differ in their specificity for the other Substrate, the L-amino acid that donates the amino group, and are named for the amino group donor. The reactions catalyzed by the aminotransferases are freely reversible, having an equilibrium constant of about 1.0 (AG's0 kJ/mol).
Aminotransferases are classic examples of enzymes cata lyzing bimolecular ping-pong reactions. In Such reactions the first Substrate must leave the active site before the second Substrate can bind. Thus the incoming amino acid binds to the active Site, donates its amino group to pyridoxal phosphate, and departs in the form of an O-keto acid. Then the incoming O-keto acid is bound, accepts the amino group from pyridoxamine phosphate, and departs in the form of an amino acid.
The measurement of alanine aminotransferase and aspar tate aminotransferase levels in blood Serum is an important diagnostic procedure in medicine, used as an indicator of heart damage and to monitor recovery from the damage.
The polynucleotides and polypeptides of the present invention have been identified as transaminases and/or ami notransferases as a result of their enzymatic activity.
In accordance with one aspect of the present invention, there are provided novel enzymes, as well as active fragments, analogs and derivatives thereof.
In accordance with another aspect of the present invention, there are provided isolated nucleic acid molecules encoding the enzymes of the present invention including mRNAS, cDNAs, genomic DNAS as well as active analogs and fragments of Such enzymes.
In accordance with yet a further aspect of the present invention, there is provided a proceSS for producing Such polypeptides by recombinant techniques comprising cultur ing recombinant prokaryotic and/or eukaryotic host cells, containing a nucleic acid Sequence of the present invention, In accordance with yet a further aspect of the present invention, there is provided a proceSS for utilizing Such enzymes, or polynucleotides encoding Such enzymes for transferring an amino group from an a-amino acid to an a-keto acid. Most transaminases use L-amino acids as Substrates, but as described below, it is also possible to convert the transaminases of the invention to use D-amino acids as Substrates, thereby increasing their array of uses to include, for example, manufacture of Synthetic pyrethroids and as components of B-lactam antibiotics. The transami nases of the invention are stable at high temperatures and in organic Solvents and, thus, are Superior for use with L and/or D-amino acids for production of optically pure chiral compounds used in pharmaceutical, agricultural and other chemical industries.
In accordance with yet a further aspect of the present invention, there are also provided nucleic acid probes com prising nucleic acid molecules of Sufficient length to hybrid ize to a nucleic acid Sequence of the present invention.
In accordance with yet a further aspect of the present invention, there is provided a proceSS for utilizing Such enzymes, or polynucleotides encoding Such enzymes, for in Vitro purposes related to Scientific research, for example, to generate probes for identifying Similar Sequences which might encode similar enzymes from other organisms by using certain regions, i.e., conserved Sequence regions, of the nucleotide Sequence.
The following drawings are illustrative of embodiments of the invention and are not meant to limit the Scope of the invention as encompassed by the claims.
FIG. 1 is a diagramatic illustration of the assay used to assess aminotransferase activity of the proteins using glutamate dehydrogenase.
The term "gene" means the segment of DNA involved in producing a polypeptide chain; it includes regions preceding and following the coding region (leader and trailer) as well as intervening sequences (introns) between individual cod ing Segments (exons).
A coding Sequence is "operably linked to another cod ing Sequence when RNA polymerase will transcribe the two coding Sequences into a Single mRNA, which is then trans lated into a single polypeptide having amino acids derived from both coding Sequences. The coding Sequences need not be contiguous to one another So long as the expressed Sequences ultimately process to produce the desired protein.
"Recombinant' enzymes refer to enzymes produced by recombinant DNA techniques, i.e., produced from cells transformed by an exogenous DNA construct encoding the desired enzyme. "Synthetic' enzymes are those prepared by chemical Synthesis.
A DNA "coding Sequence of or a "nucleotide Sequence encoding a particular enzyme, is a DNA sequence which is transcribed and translated into an enzyme when placed under the control of appropriate regulatory Sequences.
In accordance with an aspect of the present invention, there are provided isolated nucleic acids (polynucleotides) Aquifex VF5 is a Eubacteria which was isolated in Vulcano, Italy. It is a gram-negative, rod-shaped, strictly chemolithoautotrophic, marine organism which grows opti mally at 85°-90° C. (T=95° C) at pH 6.8 in a high salt culture medium with O. as a substrate, and H/CO+0.5% O2 in gas phase.
Ammonifex degensii KC4 is a new Eubacaterial organism isolated in Java, Indonesia. This Gram negative chem olithoautotroph has three respiration Systems. The bacterium can utilize nitrate, Sulfate, and Sulfur. The organism grows optimally at 70° C., and pH 7.0, in a low salt culture medium with 0.2% nitrate as a Substrate and H2/CO2 in gas phase.
Pyrobaculum aerophilium IM2 is a thermophilic sulfur archaea (Crenarchaeota) isolated in Ischia Maronti, Italy. It is a rod-shaped organism that grows optimally at 100° C. at pH 7.0 in a low salt culture medium with nitrate, yeast extract, peptone, and O. as Substrates and N/CO, O, in gas phase. Accordingly, the polynucleotides and enzymes encoded thereby are identified by the organism from which they were isolated, and are sometimes hereinafter referred to as "VF5/ ATA" (SEQ ID NOS: 17 and 25), "VF5/AAB" (SEQ ID NOS: 18 and 26), "VF5/A87A" (SEQ ID NOS:19 and 27), "VF5/AOA" (SEQ ID NOS:20 and 28), "KC4/AA" (SEQ ID NOS:21 and 29), "VF5/GF6PA" (SEQ ID NOS:22 and 30), "VF5/HPA" (SEQ ID NOS:23 and 31) and "IM2/BCA." (SEQ ID NOS:24 and 32).
The polynucleotides and polypeptides of the present invention show identity at the nucleotide and protein level to known genes and proteins encoded thereby as shown in Table 1 . All the clones identified in Table 1 encode polypeptides which have transaminase or aminotransferase activity.
One means for isolating the nucleic acid molecules encoding the enzymes of the present invention is to probe a gene library with a natural or artificially designed probe Interscience, New York, 1989 York, , 1992 . It is appreciated by one skilled in the art that the polynucleotides of SEQ ID Other particularly useful probes for this purpose are hybrid izable fragments of the sequences of SEQID NOS: 1-9 (i.e., comprising at least 12 contiguous nucleotides).
With respect to nucleic acid Sequences which hybridize to specific nucleic acid Sequences disclosed herein, hybrid ization may be carried out under conditions of reduced Stringency, medium Stringency or even Stringent conditions. AS an example of oligonucleotide hybridization, a polymer membrane containing immobilized denatured nucleic acids is first prehybridized for 30 minutes at 45 C. in a solution consisting of 0.9 M. NaCl, 50 mM NaH2PO, pH 7.0, 5.0 mM NaFDTA, 0.5% SDS, 10X Denhardt's, and 0.5 mg/mL polyriboadenylic acid. Approximately 2x10 cpm (specific activity 4-9x10 cpm/ug) of p end-labeled oligonucleotide probe are then added to the solution. After 12-16 hours of incubation, the membrane is washed for 30 minutes at room temperature in 1X SET (150 mM NaCl, 20 mM Tris hydrochloride, pH 7.8, 1 mM NaEDTA) containing 0.5% SDS, followed by a 30 minute wash in fresh 1X SET at Tm -10°C. (Tm is minus 10°C.) for the oligo-nucleotide probe.
The membrane is then exposed to auto-radiographic film for detection of hybridization signals.
Stringent conditions means hybridization will occur only if there is at least 90% identity, preferably at least 95% identity and most preferably at least 97% identity between the Sequences. See J. Sambrook et al., Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory (1989) which is hereby incorporated by reference in its entirety.
As used herein, a first DNA (RNA) sequence is at least 70% and preferably at least 80% identical to another DNA (RNA) sequence if there is at least 70% and preferably at least a 80% or 90% identity, respectively, between the bases of the first Sequence and the bases of the another Sequence, when properly aligned with each other, for example when aligned by BLASTN.
The present invention relates to polynucleotides which differ from the reference polynucleotide such that the changes are Silent changes, for example the change does not or the changes do not alter the amino acid Sequence encoded by the polynucleotide. The present invention also relates to nucleotide changes which result in amino acid Substitutions, additions, deletions, fusions and truncations in the polypep tide encoded by the reference polynucleotide. In a preferred aspect of the invention these polypeptides retain the same biological action as the polypeptide encoded by the refer ence polynucleotide.
The polynucleotides of this invention were recovered from genomic gene libraries from the organisms listed in Table 1 . Gene libraries were generated in the Lambda ZAP II cloning vector (Stratagene Cloning Systems). Mass exci Sions were performed on these libraries to generate libraries in the pBlueScript phagemid. Libraries were generated and excisions were performed according to the protocols/ methods hereinafter described. which does not substantially alter the function of the encoded enzyme. Also, using directed and other evolution Strategies, one may make very minor changes in DNA Sequence which can result in major changes in function.
Fragments of the full length gene of the present invention may be used as hybridization probes for a cDNA or a genomic library to isolate the full length DNA and to isolate other DNAS which have a high sequence similarity to the gene or Similar biological activity. Probes of this type preferably have at least 10, preferably at least 15, and even more preferably at least 30 bases and may contain, for example, at least 50 or more bases. The probe may also be used to identify a DNA clone corresponding to a full length transcript and a genomic clone or clones that contain the complete gene including regulatory and promotor regions, exons and introns. An example of a Screen comprises isolating the coding region of the gene by using the known DNA sequence to Synthesize an oligonucleotide probe. Labeled oligonucleotides having a Sequence complementary or identical to that of the gene or portion of the gene Sequences of the present invention are used to Screen a library of genomic DNA to determine which members of the library the probe hybridizes to.
It is also appreciated that Such probes can be and are preferably labeled with an analytically detectable reagent to facilitate identification of the probe. Useful reagents include but are not limited to radioactivity, fluorescent dyes or enzymes capable of catalyzing the formation of a detectable product. The probes are thus useful to isolate complemen tary copies of DNA from other Sources or to Screen Such Sources for related Sequences.
The present invention further relates to polynucleotides which hybridize to the hereinabove-described sequences if there is at least 70%, preferably at least 90%, and more preferably at least 95% identity between the sequences. The present invention particularly relates to polynucleotides which hybridize under Stringent conditions to the hereinabove-described polynucleotides. AS herein used, the term "stringent conditions' means hybridization will occur only if there is at least 95% and preferably at least 97% identity between the Sequences. The polynucleotides which hybridize to the hereinabove described polynucleotides in a preferred embodiment encode enzymes which either retain Substantially the same biological function or activity as the mature enzyme encoded by the DNA of SEQ ID NOS: 17-24. Alternatively, the polynucleotide may have at least 15 bases, preferably at least 30 bases, and more preferably at least 50 bases which hybridize to any part of a polynucle otide of the present invention and which has an identity thereto, as hereinabove described, and which may or may not retain activity. For example, Such polynucleotides may be employed as probes for the polynucleotides of SEQ ID NOS: 17-24, for example, for recovery of the polynucle otide or as a diagnostic probe or as a PCR primer.
Thus, the present invention is directed to polynucleotides having at least a 70% identity, preferably at least 90% identity and more preferably at least a 95% identity to a polynucleotide which encodes the enzymes of SEQ ID NOS:25-32 as well as fragments thereof, which fragments have at least 15 bases, preferably at least 30 bases and most preferably at least 50 bases, which fragments are at least 90% identical, preferably at least 95% identical and most preferably at least 97% identical under stringent conditions to any portion of a polynucleotide of the present invention.
The present invention further relates to enzymes which have the deduced amino acid sequences of SEQ ID NOS: 17-24 as well as fragments, analogs and derivatives of Such enzyme.
The terms "fragment," "derivative" and "analog when referring to the enzymes of SEQ ID NOS:25-32 means enzymes which retain essentially the same biological func tion or activity as Such enzymes. Thus, an analog includes a proprotein which can be activated by cleavage of the pro protein portion to produce an active mature enzyme.
The enzymes of the present invention may be a recom binant enzyme, a natural enzyme or a Synthetic enzyme, preferably a recombinant enzyme.
The fragment, derivative or analog of the enzymes of SEQID NOS:25-32 may be (i) one in which one or more of the amino acid residues are Substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and Such Substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a Substituent group, or (iii) one in which the mature enzyme is fused with another compound, Such as a com pound to increase the half-life of the enzyme (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the mature enzyme, Such as a leader or Secretory Sequence or a Sequence which is employed for purification of the mature enzyme or a proprotein Sequence. Such fragments, derivatives and analogs are deemed to be within the Scope of those skilled in the art from the teachings herein.
The enzymes and polynucleotides of the present inven tion are preferably provided in an isolated form, and pref erably are purified to homogeneity.
The term "isolated" means that the material is removed from its original environment (e.g., the natural environment 5,814,473 7 if it is naturally occurring). For example, a naturally occurring polynucleotide or enzyme present in a living animal is not isolated, but the same polynucleotide or enzyme, Separated from Some or all of the coexisting mate rials in the natural System, is isolated. Such polynucleotides could be part of a vector and/or Such polynucleotides or enzymes could be part of a composition, and still be isolated in that Such vector or composition is not part of its natural environment.
The enzymes of the present invention include the enzymes of SEQ ID NOS:25-32 (in particular the mature enzyme) as well as enzymes which have at least 70% similarity (preferably at least 70% identity) to the enzymes of SEQ ID NOS:25-32 and more preferably at least 90% similarity (more preferably at least 90% identity) to the enzymes of SEQID NOS:25-32 and still more preferably at least 95% similarity (still more preferably at least 95% identity) to the enzymes of SEQ ID NOS:25-32 and also include portions of Such enzymes with Such portion of the enzyme generally containing at least 30 amino acids and more preferably at least 50 amino acids.
As known in the art "similarity" between two enzymes is determined by comparing the amino acid Sequence and its conserved amino acid Substitutes of one enzyme to the Sequence of a Second enzyme.
A variant, i.e. a "fragment", "analog" or "derivative" polypeptide, and reference polypeptide may differ in amino acid Sequence by one or more Substitutions, additions, deletions, fusions and truncations, which may be present in any combination.
Among preferred variants are those that vary from a reference by conservative amino acid Substitutions. Such Substitutions are those that Substitute a given amino acid in a polypeptide by another amino acid of like characteristics. Typically Seen as conservative Substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu and Ile, interchange of the hydroxyl residues Ser and Thr, exchange of the acidic residues ASp and Glu, Substitution between the amide residues ASn and Gln, eXchange of the basic residues LyS and Arg and replacements among the aromatic residues Phe, Tyr.
Most highly preferred are variants which retain the same biological function and activity as the reference polypeptide from which it varies.
Fragments or portions of the enzymes of the present invention may be employed for producing the corresponding full-length enzyme by peptide Synthesis, therefore, the frag ments may be employed as intermediates for producing the full-length enzymes. Fragments or portions of the poly nucleotides of the present invention may be used to Synthe Size full-length polynucleotides of the present invention.
The present invention also relates to Vectors which include polynucleotides of the present invention, host cells which are genetically engineered with Vectors of the inven tion and the production of enzymes of the invention by recombinant techniques.
Host cells are genetically engineered (transduced or transformed or transfected) with the vectors of this invention which may be, for example, a cloning vector Such as an expression vector. The vector may be, for example, in the form of a plasmid, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, Selecting transfor mants or amplifying the genes of the present invention. The culture conditions, Such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan. The polynucleotides of the present invention may be employed for producing enzymes by recombinant tech niques. Thus, for example, the polynucleotide may be included in any one of a variety of expression vectors for expressing an enzyme. Such vectors include chromosomal, nonchromosomal and Synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; bacu lovirus; yeast plasmids, vectors derived from combinations of plasmids and phage DNA, Viral DNA Such as vaccinia, adenovirus, fowlpox virus, and pseudorabies. However, any other vector may be used as long as it is replicable and viable in the host.
The appropriate DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA Sequence is inserted into an appropriate restriction endonu clease site(s) by procedures known in the art. Such proce dures and others are deemed to be within the Scope of those skilled in the art.
The DNA sequence in the expression vector is opera tively linked to an appropriate expression control Sequence (s) (promoter) to direct MRNA synthesis. As representative examples of Such promoters, there may be mentioned: LTR or SV40 promoter, the E. coli. lac or trp, the phage lambda P, promoter and other promoters known to control expres Sion of genes in prokaryotic or eukaryotic cells or their Viruses. The expression vector also contains a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate Sequences for amplifying expression.
In addition, the expression vectors preferably contain one or more Selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydro folate reductase or neomycin resistance for eukaryotic cell culture, or Such as tetracycline or amplicillin resistance in E.
coli.
The Vector containing the appropriate DNA sequence as hereinabove described, as well as an appropriate promoter or control Sequence, may be employed to transform an appro priate host to permit the host to express the protein.
AS representative examples of appropriate hosts, there may be mentioned: bacterial cells, Such as E. coli, Streptomyces, Bacillus Subtilis, fungal cells, Such as yeast; insect cells such as Drosophila S2 and Spodoptera Sf9; animal cells Such as CHO, COS or Bowes melanoma; adenoviruses, plant cells, etc. The Selection of an appropri ate host is deemed to be within the scope of those skilled in the art from the teachings herein.
More particularly, the present invention also includes recombinant constructs comprising one or more of the Sequences as broadly described above. The constructs com prise a vector, Such as a plasmid or viral vector, into which a Sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further compriseS regulatory Sequences, including, for example, a promoter, operably linked to the Sequence. Large numbers of Suitable vectors and promoters are known to those of Skill in the art, and are commercially available. The following vectors are provided by way of example; Bacterial: pCE70, pCE60, pGE-9 (Qiagen), pBluescript II KS, ptrc99a, pKK223-3, pIDR540, pRI72T (Pharmacia); Eukaryotic: pXT1, pSG5 (Stratagene) pSVK3, pBPV, pMSG, pSVL SV40 (Pharmacia). However, any other plasmid or vector may be used as long as they are replicable and viable in the host.
Promoter regions can be selected from any desired gene using In a further embodiment, the present invention relates to host cells containing the above-described constructs. The host cell can be a higher eukaryotic cell, Such as a mam malian cell, or a lower eukaryotic cell, Such as a yeast cell, or the host cell can be a prokaryotic cell, Such as a bacterial cell. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)).
The constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recom binant Sequence. Alternatively, the enzymes of the invention can be Synthetically produced by conventional peptide Syn Transcription of the DNA encoding the enzymes of the present invention by higher eukaryotes is increased by inserting an enhancer Sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp that act on a promoter to increase its transcription. Examples include the SV40 enhancer on the late side of the replication origin bp 100 to 270, a cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.
Generally, recombinant expression vectors will include origins of replication and Selectable markers permitting transformation of the host cell, e.g., the amplicillin resistance gene of E. coli and S. cerevisiae TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream Structural Sequence. Such promoters can be derived from operons encoding glycolytic enzymes Such as 3-phosphoglycerate kinase (PGK), C.-factor, acid phosphatase, or heat Shock proteins, among others. The heterologous Structural Sequence is assembled in appropriate phase with translation initiation and termination Sequences, and preferably, a leader Sequence capable of directing Secre tion of translated enzyme. Optionally, the heterologous Sequence can encode a fusion enzyme including an N-terminal identification peptide imparting desired characteristics, e.g., Stabilization or Simplified purification of expressed recombinant product.
Useful expression vectors for bacterial use are con Structed by inserting a Structural DNA sequence encoding a desired protein together with Suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will comprise one or more phenotypic Selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, pro vide amplification within the host. The enzymes of the present invention may be a naturally purified product, or a product of chemical Synthetic procedures, or produced by recombinant techniques from a prokaryotic or eukaryotic host (for example, by bacterial, yeast, higher plant, insect and mammalian cells in culture).
Depending upon the host employed in a recombinant pro duction procedure, the enzymes of the present invention may be glycosylated or may be non-glycosylated. Enzymes of the invention may or may not also include an initial methionine amino acid residue.
Transaminases are a group of key enzymes in the metabolism of amino acids and amino Sugars and are found in all organisms from microbes to mammals. In the tran Samination reaction, an amino group is transferred from an amino acid to an O-keto acid. Pyridoxal phosphate is required as a co-factor to mediate the transfer of the amino group without liberation of ammonia. There are a number of reasons to employ transaminases in industrial-scale production of amino acids and their 4) The capital investment for an immobilized enzyme proceSS using transaminases is much lower than for a large Scale fermentation process, and productivity of the bioreac tor is often an order of magnitude higher.
5) The technology is generally applicable to a broad range of D-or L-amino acids because transaminases exist with varying Specificities. Such broad Scope allows a num ber of different L-or D-amino acids to be produced with the Same equipment and often the same biocatalyst.
Antibodies generated against the enzymes corresponding to a Sequence of the present invention can be obtained by direct injection of the enzymes into an animal or by admin istering the enzymes to an animal, preferably a nonhuman. The antibody so obtained will then bind the enzymes itself. In this manner, even a Sequence encoding only a fragment of the enzymes can be used to generate antibodies binding the whole native enzymes. Such antibodies can then be used to isolate the enzyme from cells expressing that enzyme. The present invention will be further described with reference to the following examples; however, it is to be understood that the present invention is not limited to Such examples. All parts or amounts, unless otherwise Specified, are by weight.
In order to facilitate understanding of the following examples certain frequently occurring methods and/or terms will be described. "Plasmids" are designated by a lower case "p' preceded and/or followed by capital letters and/or num bers. The Starting plasmids herein are either commercially available, publicly available on an unrestricted basis, or can be constructed from available plasmids in accord with published procedures. In addition, equivalent plasmids to those described are known in the art and will be apparent to the ordinarily skilled artisan. "Digestion" of DNA refers to catalytic cleavage of the DNA with a restriction enzyme that acts only at certain Sequences in the DNA. The various restriction enzymes used herein are commercially available and their reaction conditions, cofactors and other require ments were used as would be known to the ordinarily skilled artisan. For analytical purposes, typically 1 lug of plasmid or DNA fragment is used with about 2 units of enzyme in about 20 ul of buffer solution. For the purpose of isolating DNA fragments for plasmid construction, typically 5 to 50 lug of DNA are digested with 20 to 250 units of enzyme in a larger Volume. Appropriate buffers and Substrate amounts for par ticular restriction enzymes are specified by the manufac turer. Incubation times of about 1 hour at 37 C. are ordinarily used, but may vary in accordance with the Sup plier's instructions. After digestion the reaction is electro phoresed directly on a polyacrylamide gel to isolate the desired fragment.
Size Separation of the cleaved fragments is performed using 8 percent polyacrylamide gel described by Goeddelet al., Nucleic Acids Res., 8:4057 (1980) . "Oligonucleotides' refers to either a Single Stranded poly deoxynucleotide or two complementary poly deoxy nucleotide Strands which may be chemically Synthesized. Such Synthetic oligonucleotides have no 5" phosphate and thus will not ligate to another oligonucleotide without add ing a phosphate with an ATP in the presence of a kinase. A Synthetic oligonucleotide will ligate to a fragment that has not been dephosphorylated.
"Ligation" refers to the process of forming phosphodi ester bonds between two double Stranded nucleic acid frag ments (Maniatis, T, et al., Id., p. 146 DNA encoding the enzymes of the present invention, SEQ ID NOS:25 through 32, were initially amplified from a pBluescript vector containing the DNA by the PCR tech nique using the primers noted herein. The amplified Sequences were then inserted into the respective PQE vector listed beneath the primer Sequences, and the enzyme was expressed according to the protocols Set forth herein. The genomic DNA has also been used as a template for the PCR amplification, i.e., once a positive clone has been identified and primer Sequences determined using the cDNA, it was then possible to return to the genomic DNA and directly amplify the desired sequence(s) there. The 5' and 3' primer The restriction enzyme sites indicated correspond to the restriction enzyme sites on the bacterial expression vector indicated for the respective gene (Qiagen, Inc. Chatsworth, Calif.). The pGE vector encodes antibiotic resistance (Amp'), a bacterial origin of replication (ori), an IPTG regulatable promoter operator (P/O), a ribosome binding site (RBS), a 6His tag and restriction enzyme sites.
The pGE vector was digested with the restriction enzymes indicated. The amplified Sequences were ligated into the respective pGE vector and inserted in frame with the Sequence encoding for the RBS. The ligation mixture was then used to transform the E. coli strain M15/pREP4 (Qiagen, Inc.) by electroporation. M15/pREP4 contains multiple copies of the plasmid pREP4, which expresses the lacl repressor and also confers kanamycin resistance (Kan').
Transformants were identified by their ability to grow on LB plates and amplicillin?kanamycin resistant colonies were selected. Plasmid DNA was isolated and confirmed by restriction analysis. Clones containing the desired constructs were grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture was used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells were grown to an optical density 600 (O.D.) of between 0.4 and 0.6. IPTG ("Isopropyl-B-D-thiogalacto pyranoside') was then added to a fmal concentration of 1 mM. IPTG induces by inacti Vating the lacI repressor, clearing the P/O leading to increased gene expression. Cells were grown an extra 3 to 4 hours. Cells were then harvested by centrifugation.
The primer Sequences Set out above may also be employed to isolate the target gene from the deposited material by hybridization techniques described above. 
